Research On Supply Chain Financing Model Of Small And Medium - Sized Pharmaceutical Enterprises

SMEs have an extremely important role in the economic development of countries aroundthe world, and plays an active role in the protection of employment, to ensure economic andsocial stability, to maintain market competitiveness, optimizing the economic structure andlayout. According to statistics, China’s existing small and medium enterprises accounted forabout99%of the total number of domestic companies, and the value of final goods and servicesthey create are accounted for about50percent of China’s GDP, while domestic employment tosolve the total amount of urban employment more than75%of the amount of tax revenueaccounted for43.2%completed the country’s total tax revenue. However, small and mediumenterprises in their growth, development process, but often encounter the problem of shortage offunds difficult to solve many markets, and gradually restricted its healthy and sustainabledevelopment of the main bottlenecks. Modern bio-pharmaceutical industry is the world’s fastestgrowing industry, one of the most promising countries in the world have increased to varyingdegrees, the amount of investment in the industry, and China is no exception. However, due tothe modern pharmaceutical industry has high investment, high risk, technology-intensivefeatures, and it has been showing up financing.From the current situation of SME financing to start, innovation and development ofcommercial bank financing of new ways of business-financial services supply chain in-depthanalysis and research. Now for the study of small and medium domestic pharmaceuticalenterprises financing difficulties tend to issue more financial support system, credit guaranteesystem, the establishment of small and medium sized financial institutions and other aspects.Small and medium sized pharmaceutical companies as a special class of business groups, bothplay an important role in our livelihoods, but also for economic development made an importantcontribution. However, due to many factors, the financing difficulties of small and medium sizedpharmaceutical companies that have been unable to get an effective solution to the dilemma, oreven directly as a constraint to the healthy development of small and medium sizedpharmaceutical companies hindered. So, how to solve the dilemma of financing small andmedium pharmaceutical companies, so that in the national economy, the domestic production ofpharmaceutical research and development play a greater role, which is also an important issue I currently worth further study.The emergence of supply chain finance, to address domestic enterprises and financialinstitutions between objectively existing "borrow""not prime" dilemma. As we all know, supplychain finance is a new mode of financing credit, is to promote various bank credit to small andmedium enterprises to gradually shift to investigate these SMEs in the supply chain,"status","importance" as well as the core business transactions such as credit status inspection; abandonthe original model of the enterprise credit funds demand, and to how to meet the supply chain asa whole, sustainable financing needs of its ultimate goal. Therefore, supply chain finance andfinancing difficulties of SMEs appear to play a positive role in mitigation; at the same time, theproblem of information asymmetry between small and medium enterprises and financialinstitutions to play an effective role to resolve. Meanwhile, the author of the root causes ofdomestic and SME financing carding, supply chain finance research base on the financing model,supply chain finance further proposed mechanism of action of pharmaceutical companies in theSME financing in order to mitigate or resolve the domestic small and medium sizedpharmaceutical companies financing issues to provide more information.This paper is divided into six parts. Chapter One: The main article describes the background,the research object, meaning and methods and literature review SME supply chain financing, andon the root causes of financing difficulties of small and medium pharmaceutical companies,Solutions were analyzed, but also on the supply chain of financial solutions for small andmedium pharmaceutical companies to sort out the financial-related documents. Chapter II:domestic small and medium pharmaceutical companies’ financing difficulties "root causeanalysis, and based on the theoretical level related financing difficulties and future developmenttrends are one by one. Chapter III: The existing supply chain financing model and credit ratinganalysis and construct elaborate. Chapter4: Analysis based on theoretical and empiricalforegoing. This chapter of a business case analysis medicine were systematically expounded.Chapter5: to promote the development of small and medium pharmaceutical companies supplychain financing proposals. This chapter begins with strengthening the financing of small andmedium pharmaceutical industry supply chain to start, make small pharmaceutical supply chainfinance product innovation, development strategies, and through the improvement of relevantlaws and regulations to provide legal support and other measures to further promote the development of small and medium sized pharmaceutical companies. Chapter6: Conclusion. Themain results of this research are summarized, and insufficient analysis were shallow and futureresearch directions.